
Claims

1. A compound of formula (I):




(I)

or a pharmaceutically acceptable salt thereof, wherein

X is O;

Y is O;

Het is 

;

R^{1a} is hydroxy;

R^{1b} is H;

R^{2a} is H or hydroxy;

R^{2b} is halo, C_{1-6}alkyl, or C_{2-6}alkynyl; or

R^{2a} and R^{2b}, together with the carbon atom to which they are attached, form a $C=CH_2$;

R^3 is H;

R^4 is $-C(O)OR^9$;

R^5 is aralkyl;

R^6 is $-C(O)OR^9$; and

R^9 is H or alkyl.

2. The compound of claim 1, wherein R^{2a} is hydroxy.

3. The compound of claim 1, wherein R^{2b} is C_{1-6}alkyl.

4. The compound of any one of claims 1-3, wherein R^{1a} is hydroxy and R^{2a} is hydroxyl and R^{2b} is C_{1-6}alkynyl.

5. The compound of any preceding claim, wherein R^5 is aralkyl, which is unsubstituted or substituted with one or more substituents, selected from halo, CN, NO_2, azido, hydroxy, alkoxy, alkylthio, thioalkoxy, carbonyl, thiocarbonyl, amidino, imino, amino, amido, alkoxycarbonyl, carbamate, urea, sulfinamido, sulfonamido,

sulfinyl, sulfinamido, sulfonyl, phosphoryl, phosphate, phosphonate, phosphinate, cycloalkyl, heterocyclyl, arylalkyl and heteroarylalkyl.

6. The compound of claim 5, wherein the substituents are selected from halo, CN, azido, alkoxy, carbonyl, amino, amido, and alkoxycarbonyl.

7. The compound of claim 1, wherein R^5 is unsubstituted or substituted with one or more substituents selected from halo, CN, OH, alkyl, alkenyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylsulfonyl, sulfonamido, amido, amino, hydroxycarbonyl, alkoxycarbonyl, heteroaryl, aryl, aralkyl, and heteroaralkyl.

8. The compound of claim 7, wherein the substituents are selected from halo, CN, haloalkyl, haloalkoxy, carboxy, alkoxycarbonyl, and aryl.


9. The compound of claim 7, wherein the substituents are selected from tetrazolyl, substituted or unsubstituted phenyl, or substituted or unsubstituted benzyl.

10. The compound of claim 7, wherein R^5 is unsubstituted or substituted with one or more substituents, selected from chloro, trifluoromethyl, trifluoromethoxy, phenyloxy, dimethylamido, methylsulfonyl, CN, and carboxylic acid.









11. The compound of any preceding claim, wherein R^9 is H, methyl or ethyl.


12. The compound of any one of claims 1-10, wherein R^9 is alkyl, which is unsubstituted or substituted, with one or more selected from halo, CN, NO_2, azido, hydroxy, alkoxy, alkylthio, thioalkoxy, carbonyl, thiocarbonyl, amidino, imino, amino, amido, alkoxycarbonyl, carbamate, urea, sulfinamido, sulfonamido, sulfinyl, sulfinamido, sulfonyl, phosphoryl, phosphate, phosphonate, and phosphinate.


13. The compound of claim 1, wherein




represents





,



, or



.


14. The compound of claim 1, wherein





represents



,


,





















,




,















,




,


,


,

,

,

,

,

,

,

,,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





,

,

,

,

,

,

,

,

,

,

,

,

.








15. The compound of claim 1, wherein  represents  where each R_A is independently selected from H, halo, CN, OH, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylsulfonyl, sulfonamido, amido, amino, hydroxycarbonyl, alkoxycarbonyl, heteroaryl, aryl, aralkyl, and heteroaralkyl; and


k is 1, 2, or 3.

16. The compound of claim 15, wherein R_A is selected from pyridyl, pyrazolyl, pyrrolidinonyl, azapanonyl, morpholinonyl, piperazonyl, tetrahydropyrimidinonyl, phenyl, and benzyloxy.

17. A compound selected from:

Cpd. #	**Compound**
147	
148	
149	

154	
163	
164	
165	
167	
168	
173	

174	

or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

19. A method of inhibiting CD73 in a cell in vitro, comprising contacting the cell with a compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-17.

20. Use of a compound of claim 1 in the manufacture of a medicament for treating a disease or disorder selected from cancer, cerebral and cardiac ischemic diseases, fibrosis, immune and inflammatory disorders, inflammatory gut motility disorder, neurological, neurodegenerative and CNS disorders and diseases, depression, Parkinson's disease, and sleep disorders.

21. The use of claim 20, wherein the cancer is selected from bladder cancer, bone cancer, brain cancer, breast cancer, cardiac cancer, cervical cancer, colon cancer, colorectal cancer, esophageal cancer, fibrosarcoma, gastric cancer, gastrointestinal cancer, head & neck cancer, Kaposi's sarcoma, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, myeloma, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, testicular germ cell cancer, thymoma and thymic carcinoma.

22. The use of claim 21, wherein the cancer is selected from breast cancer, brain cancer, colon cancer, fibrosarcoma, kidney cancer, lung cancer, melanoma, ovarian cancer, and prostate cancer.

23. The use of claim 22, wherein the cancer is breast cancer.